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ABSTRACT
Objectives: Endometrial cancer is the most common cancer of the female genital organs in developed countries, accounting 
for approximately 50% of all gynecological cancers. The Klotho gene was discovered in 1997 as an anti-aging gene that, when 
overexpressed, may extend the lifespan, but when disrupted, may be a factor responsible for premature aging syndrome. 
The aim of the study is to assess the relationship between the clinical and pathological features of endometrial cancer and 
βKlotho gene expression.
Material and methods: The expression of βKlotho gene was studied in 138 cases of endometrioid endometrial carcinoma 
specimens using Real Time PCR reaction in RNA isolated tissue samples by commercial tests. The expression profile was 
correlated with the clinicopathological characteristics of endometrial carcinoma. The chi-square independence test and 
Fisher’s test for four-field tables were used to assess the statistical significance of the observed relationships. 
Results: Significant relationships were found between βKlotho gene expression and FIGO clinical stage, the degree of 
histological differentiation and the presence of metastases in the lymph nodes. Higher levels of gene expression correlate 
with lower degrees of clinical staging according to FIGO, the presence of highly-differentiated endometrial cancer (G1) 
and the absence of lymph node metastases. 
Conclusions: The βKlotho gene expression might be involved in endometrioid endometrial cancer tumorgenesis. The 
βKlotho may in future be used as an useful indicator for endometrial cancer, although further studies are needed.
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INTRODUCTION
Malignant neoplasms are the second most frequent cause 
of death in Poland, being responsible for more than 26% of 
deaths among men and 23% among women. Endometrial 
cancer is the most common cancer of the female genital organs 
in developed countries, accounting for approximately 50% 
of all gynecological cancers. In Poland, in 2013, 5706 women 
were diagnosed with this cancer and 1243 died. The abnormal 
expression of Klotho proteins, as well as mutations in the 
genes encoding them, have been demonstrated in the case 
of prostate, bladder, lung or stomach cancer [1]. In recent 
years, it has also been proven that these disorders can play 
a significant role in the development of breast, ovarian and 
endometrial cancers.
The Klotho gene was discovered in 1997 as an anti-
aging gene that, when overexpressed, may extend the life 
span, but when disrupted, may be a factor responsible for 
premature aging syndrome [2, 3]. The name of the gene 
and protein is derived from the Greek goddess Klotho, 
who spun the thread of human life and decided on its 
length [4, 5]. The human Klotho gene (KL) consists of five 
exons and four introns located on chromosome 13, and 
produces two transcript forms, these being known as the 
intraepithelial and secretory forms. The form secreted into 
the bloodstream, i.e. the secretory form, is created by the 
excision of the endothelial domain from the full transcript, 
i.e. the intraepithelial form, consisting of 1014 amino 
acids. While the membrane Klotho protein is expressed at 
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a higher level in mice [6], the secretory form predominates 
in humans [7].
The signal sequences of the Klotho gene are found 
at its N-terminus, and the membrane domain and short 
cytoplasmic domain at the C-terminus. The Klotho part of 
the transmembrane segment consists of two repeats inside 
the gene (KL1 and KL2) that divides the homology sequence 
with β-glucosidase [8]. KL1 and KL2 are components of the 
Klotho protein structure.
In 2000, the βKlotho gene (KLB) coding for the monotop-
ic transmembrane protein was discovered as a homologue 
of the αKlotho gene (αKL — Mouse Klotho α gene) of mice 
[5]. The KLB gene consists of five exons and four introns; 
however, while the mouse form is 35.59 kbp and located on 
chromosome 5, the human form measures 44.68 kbp and 
is found on chromosome 4. The expression profile of KLB 
is significantly different from that of the αKlotho gene: In 
mice, βKlotho gene expression occurs primarily in the liver 
and pancreas, while KLB expression is observed in the skin, 
skeletal muscle, stomach, small intestine and lung [9–11]. 
In humans, KLB expression has been detected mainly in the 
liver, adipose tissue and breast tissue, and to a lesser extent 
in the spleen, testes, prostate, eyeball and brain [12].
The transmembrane protein βKlotho has a molecular 
mass of 119.8 kDa and is a homologue of the αKlotho protein; 
in humans, the two proteins demonstrate approximately 
41.2% amino acid compatibility [13], while the mouse and 
human forms of the β-Klotho protein share 79% similarity 
[14]. Three domains are distinguished in the structure of the 
βKlotho protein: a C-terminal extracellular domain, an intra-
membrane domain and a short cytoplasmic domain [15].
In addition, unlike αKlotho, previous studies have 
not shown that the βKlotho gene transcript undergoes 
an alternative assembly process that would result in the 
secretion of this protein. The αKlotho protein possesses 
a short amino acid sequence (KKRK), within which the 
protein is proteolytically cleaved; however, this sequence 
is lacking from the βKL2 region [9].
βKlotho interacts with the endocrine growth factors 
FGF21 and FGFR1, which transmit the biological cellular 
response via growth factor receptors (FGFR).
Aim of the study
The aim of the study is to determine the relationship 
between the clinical and pathological features of 
endometrial cancer and βKlotho gene expression.
The study analyses the relationship between the range 
of βKlotho expression and the FIGO (Fédération Internation-
ale de Gynécologie et d’Obstétrique) stage, the histological 
differentiation and the presence of lymph node metastases 
in endometrial cancer.
MATERIAL AND METHODS
The design of the study was presented and approved 
by the Ethical Committee of the Medical University of Lodz 
(RNN/617/14/KB). All patients participating in the study 
gave their informed consent to take part. The samples of 
cancer tumor tissue were collected from 138 patients treated 
surgically in the Department of Gynecological Oncology, 
Medical University of Lodz for endometrioid endometrial 
cancer. The mode of treatment was determined following 
pathological examination of endometrial tissue, collected 
before surgery; participation in the study had no influence 
on therapeutic decisions. In the examined group of patients, 
fresh cancer tissue samples taken from the removed uterus 
were immediately placed in RNAlater (Ambion, USA) and 
stored at -80°C for subsequent RNA extraction and testing.
Gene expression analysis was carried out as follows.
RNA isolation
The fragmented tissue samples were suspended in 500 μl 
buffer containing 10 mM NaCl, 500 mM Tris (pH 7.6), 20 mM 
EDTA, 1% SDS and 500 μl/mL proteinase K and incubated 
at 50°C for eight hours. The RNA was then isolated from the 
lysates obtained using 500 μl of TRI Reagent: TRI (Total RNA 
Isolation) is a mixture of phenol, guanidine isothiocyanate 
and other compounds causing cell lysis and inactivation of 
endogenous RNases. After 10 minutes of incubation at room 
temperature, 200 μl of chloroform was added and mixed 
for 30 s using a shaker. The samples were then centrifuged 
at 4°C for 15 minutes at 12,000 x g. The aqueous phase was 
transferred to a new tube, 500 μl isopropanol was then added 
and the contents of the tube were mixed. After 15 minutes 
of incubation at room temperature, the samples were centri-
fuged at 4°C for 10 minutes at 12,000 xg. The supernatant was 
removed and 1 mL of 75% ethanol was added to the pellet of 
RNA. Samples were then centrifuged at 4°C for five minutes 
at 12,000 x g. After removal of the supernatant, the pellet was 
dried at room temperature for five minutes. The pellet was 
resuspended in 20 μl of water lacking ribonuclease activity 
using DEPC. RNA samples were stored at -20°C. Spectropho-
tometric analysis was then performed to evaluate the purity 
and concentration of RNA and DNA.
The purity of the obtained RNA preparations was 
determined spectrophotometrically by measuring the 
absorbance of each sample at 260 nm and 280 nm. The 
accepted criterion for DNA and RNA purity was the value 
A260/A280, which was within 1.8–2.0. The RNA concentration 
was determined by measuring the absorbance at 260 nm. 
This value corresponds to the following relationship:
•	 1 OD = 40 μg RNA/mL,
•	 analysis of βKlotho gene expression at the mRNA level,
•	 reverse transcription reaction.
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The reverse transcription reaction was performed using 
the High Capacity cDNA Reverse Transcription Kit according 
to the manufacturer’s instructions. First, 2 μg of total RNA 
(1 μg/μl) was suspended in a 20 μl mixture containing 2 μl 
of 10 × RT Buffer, 0.8 μl dNTP (100 μM), 2 μl of 10 × RT 
Random Primers, 1 μl of MultiScribe Reverse Transcriptase, 
1 μl RNase inhibitor, 11.2 μl of DEPC treated water. The 
prepared samples were incubated for 10 minutes at 25°C, 
followed by 120 minutes at 37°C and 5 minutes at 85°C. The 
obtained cDNA was stored at -20°C.
PCR reaction with real-time product volume 
increase analysis (Real-Time PCR)
The Real-Time PCR (polymerase chain reaction) reaction 
allows the number of copies of the mRNA of a particular 
gene to be determined in an original sample using gene-
specific probes labeled with fluorescent dyes. The reaction 
contained 0.5 μl of cDNA, 0.5 μl of 20 x TaqMan® Gene 
Expression Assays, 5 μl TaqMan® Universal PCR MasterMix 
containing TaqMan® DNA polymerase, dNTP, reaction buffer 
and 4 μl of water. The Real Time PCR reaction was carried out 
in the Mastercycler® ep realplex thermal cycler according 
to the following program: pre-denaturation at 95°C for 
10 minutes followed by 50 cycles of incubation at 95°C for 
15 s and at 60°C for one minute.
The standard commercial probe and primer sets were 
used in the Real Time PCR reaction. The obtained Ct values 
were converted into the number of mRNA copies of the 
βKlotho gene per 1000 copies of HPRT1 mRNA according 
to the following relationships:
•	 ΔCt = Ct of the test gene - Ct of the reference gene,
•	 L = 1000 2-ΔCt,
(where: L — number of mRNA copies of the tested gene / 
1,000 copies of the mRNA of the reference gene).
Statistical methods
A statistical analysis was performed of the clinical and 
pathological parameters of the examined material. The Chi-
square independence test was used to assess the statistical 
significance of the observed relationships. In cases where 
the assumptions for the said test were not met (e.g. fewer 
than five examples of any one field), Fisher’s test for four-
field tables was used. A value of p < 0.05 was considered 
statistically significant
Continuous variables were coded into qualitative variables 
based on quartile values before analysis using the chi-square 
or Fisher’s test. As the therapeutic process had no effect in 
some cases, the total number of patients included in the 
individual calculations may be smaller than the total number 
of patients enrolled in the study. Patients who underwent 
surgery without lymphadenectomy are not included in the 
calculations, including the assessment of the dependence 
of the expression of the examined genes on the metastases 
of cancer to the lymph nodes. Statistical calculations and 
graphs were created using STATISTICA12 software (StatSoft).
RESULTS
For statistical analysis, βKlotho gene expression was 
divided into five categories. Category 1 consisted of cases 
for which the expression was absent. For non-zero values 
of gene expression, the values of subsequent quartiles 
were calculated. Category 2 included cases for which the 
expression value was no higher than the first quartile 
value. Category 3 included cases between the first quartile 
and the median. Category 4 included cases between the 
median value and the third quartile value. Any case where 
expression was greater than the third quartile was classified 
as category 5. The exact assignment of individual values to 
categories is provided in Table 1.
The analysis was started by examining the relationship 
between the range of βKlotho expression values and FIGO 
clinical stage.
The relationship between the range of βKlotho 
expression values and the FIGO clinical stage
The analysis indicates that higher FIGO stages (i.e. 3 or 4) 
occur almost exclusively when βKlotho gene expression was 
absent (see Tab. 2). When βKlotho expression was present, 
stage FIGO1 (around 90%) was found to predominate. 
A statistically significant relationship was found between 
the occurrence of βKlotho gene expression and the clinical 
stage of FIGO (chi2 = 44.35, p < 0.001).







cases [%] of cases
1 0 64 46.4%
2 2.13–19.76 19 13.8%
3 21.07–47.13 18 13.0%
4 47.16–79.35 18 13.0%
5 80.26–118.2 19 13.8%
Total 0–118.2 138 100%
Table 2. The relationship between the expression of the βKlotho 
gene and the clinical stage of FIGO




FIGO: 2, 2A, 2B, 
3, 3A, 3B, 3C, 4B Total
0 24 (38.1%) 39 (61.9%) 63 (100%)
2.13–118.2 66 (90.4%) 7 (9.6%) 73 (100%)
Total 90 (66.2%) 46 (33.8%) 136 (100%)
Statistical 
analysis Chi
2 = 44.35; p = 0.0000
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The relationship between the range of βKlotho 
expression values and the degree of histological 
differentiation
βKlotho gene expression was absent in all tumors at 
stage G3 (grading, the degree of histological differentiation 
of malignant tumors). At histological stage G2, while most 
cases demonstrated no expression, various levels of expres-
sion were also observed. However, at stage G1, the major-
ity of cases demonstrated high gene expression, placing 
them in category 5 (80.26–118.2). A statistically significant 
relationship was hence observed between the occurrence 
of βKlotho gene expression and the degree of histological 
differentiation (T. Fisher, p < 0.001, see Fig. 1 and Tab. 3).
The relationship between the range of βKlotho 
expression and the presence of lymph node 
metastases
An analysis of lymph node status and βKlotho gene 
expression indicates that the lymph nodes are involved 
primarily when βKlotho gene expression is absent. 
A statistically significant relationship was found between 
the occurrence of βKlotho expression and the presence of 
metastases in the lymph nodes (T. Fisher, p < 0.001, Tab. 4).
DISCUSSION
Interest is growing in the genetic aspects of the 
epigenesis of malignant tumors. The life cycle of the 
cell is controlled at the genetic level. Hence, the genetic 
mechanisms responsible for carcinogenesis are typically 
identified according to the general scheme of carcinogenesis, 
from the initiation of a genetic error, through its promotion 
and progression, to the eventual halting of its fixation by 
apoptosis.
The Klotho gene has been labelled the youth gene 
[2, 3]. Its role in the neoplastic process has been studied 
in numerous cancer processes. Immunohistochemical 
analysis has revealed high expression of Klotho in healthy 
breast tissue and very low expression in breast cancer 
tissue. In breast cancer tissue samples, high Klotho 
expression was correlated with a smaller tumor size and 
less mitotic activity. Cervical cancer studies have found 
Klotho mRNA to be absent in numerous samples of cancer 
tissue at high stages of clinical FIGO, but not in cases 
of early pre-invasive oncogenesis (carcinoma in situ); it 
has also been reported that Klotho expression returns 
to normal after treatment, indicating that significant 
reduction of Klotho expression may be associated with 
the presence of cervical cancer. Similar results have also 
been observed in the oncogenesis of colon [16], stomach 
[17] and bladder [18] cancer.
Subsequent studies have found the Klotho gene to 
play a suppressing role in the neoplastic transformation of 
bladder cancer [18].
The βKlotho gene has been an object of interest for 
many scientists [19]. Initial studies examined its role in the 
development of liver cancer but with varying results. How-
ever, most studies suggest that βKlotho inhibits the prolif-
eration of liver cancer cells. Poh et al. [20] report increased 
expression of βKlotho and FGFR4 in human liver cancer cells 
and in HCC (hepatocellular carcinoma) cell lines, suggesting 
that increased expression of KLB is associated with neo-
plastic transformation and the progression of liver cancer. 
However, other research groups have reported reduced KLB 
expression in HCC cell lines [20–22], and that restoration of 
normal KLB expression inhibited HCC proliferation.
Table 3. The expression of the βKlotho gene according to the degree 
of histological maturity
Expression of the 
βKlotho gene G1, G2 G3 Total
0 43 (68.3%) 20 (31.8%) 63 (100%)
2.13–118.2 73 (100%) 0 (0%) 73 (100%)
Total 116 (85.3%) 20 (14.7%) 136 (100%)
Statistical analysis Fisher’s test; p = 0.0000
Table 4. Relationship between the expression of the βKlotho gene 
and lymph node status








0 42 (73.7%) 15 (26.3%) 57 (100%)
2.13–118.2 65 (97.0%) 2 (3.0%) 67 (100%)
Total 107 (86.3%) 17 (13.7%) 124 (100%)
Statistical analysis T. Fisher; p = 0,0002
Figure 1. Relationship between the range of βKlotho expression 
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Until now, marked KLB expression has been observed 
in various healthy and cancerous tissues. KLB expression 
is absent in the case of endometrial cancer, or at least 
significantly lower than in healthy endometrial tissue 
[22]. The literature concerning relation between βKlotho 
and endometrial cancer is limited. Available data suggest 
decreased expression of KLB in endometrial carcinomas [23]. 
The data from our study clearly indicates that βKlotho 
is involved in the process of neoplastic transformation of 
endometrial mucosa, and that further analysis in this area is 
called for. Our findings represent a more thorough assessment 
of the activity of βKlotho with regard to clinical FIGO staging, 
lymph node infiltration and tumor malignancy grade.
The higher clinical FIGO stages, i.e. 3 or 4, were found 
to be characterised almost exclusively by absent expression 
of the βKlotho gene (Tab. 2). When expression was present, 
approximately 90% of cases were observed in clinical stage 
1. Moreover, βKlotho gene expression was always found 
to be absent in samples of histological grade G3, while it 
tended to be very low or zero for grade G2. In contrast, gene 
expression reached category 5 in our study for grade G1. In 
addition, lymph node involvement was typically associated 
with absent βKlotho gene expression, with most samples 
expressing βKlotho also demonstrating lymph nodes 
free of metastases. Statistical analysis showed a strong 
dependence of βKlotho expression on FIGO clinical stage, 
histological malignancy grade and presence of infiltrated 
lymph nodes. Our findings suggest that a lack of βKlotho 
gene expression promotes the development of neoplastic 
processes in endometrial cancer, while high βKlotho gene 
expression may act to suppress neoplastic transformation.
CONCLUSIONS
Our results support the hypothesis indicating the role 
of βKlotho gene expression in endometrioid endometrial 
cancer pathogenesis. However further studies in this field 
are needed to elucidate suggested relations. 
REFERENCES
1. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth 
factor signaling: a new therapeutic opportunity in cancer. Clin Cancer 
Res. 2012; 18(7): 1855–1862, doi: 10.1158/1078-0432.CCR-11-0699, 
indexed in Pubmed: 22388515.
2. Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev. 2009; 
8(1): 43–51, doi: 10.1016/j.arr.2008.10.002, indexed in Pubmed: 19022406.
3. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho 
gene leads to a syndrome resembling ageing. Nature. 1997; 390(6655): 
45–51, doi: 10.1038/36285, indexed in Pubmed: 9363890.
4. Kuro-o M. Klotho and aging. Biochim Biophys Acta. 2009; 1790(10): 
1049–1058, doi: 10.1016/j.bbagen.2009.02.005, indexed in Pubmed: 
19230844.
5. Kuro-o M. Klotho and βKlotho. Adv Exp Med Biol. 2012; 728: 25–40, doi: 
10.1007/978-1-4614-0887-1_2, indexed in Pubmed: 22396160.
6. Matsumura Y, Aizawa H, Shiraki-Iida T, et al. Identification of the 
human klotho gene and its two transcripts encoding membrane and 
secreted klotho protein. Biochem Biophys Res Commun. 1998; 242(3): 
626–630, indexed in Pubmed: 9464267.
7. Li SA, Watanabe M, Yamada H, et al. Immunohistochemical localization 
of Klotho protein in brain, kidney, and reproductive organs of mice. 
Cell Struct Funct. 2004; 29(4): 91–99, indexed in Pubmed: 15665504.
8. Razzaque MS. The role of Klotho in energy metabolism. Nat 
Rev Endocrinol. 2012; 8(10): 579–587, doi: 10.1038/nrendo.2012.75, 
indexed in Pubmed: 22641000.
9. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression 
analyses of mouse betaklotho, which encodes a novel Klotho family 
protein. Mech Dev. 2000; 98(1-2): 115–119, indexed in Pubmed: 
11044614.
10. Ito S, Fujimori T, Furuya A, et al. Impaired negative feedback suppression 
of bile acid synthesis in mice lacking βKlotho. Journal of Clinical 
Investigation. 2005; 115(8): 2202–2208, doi: 10.1172/jci23076.
11. Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for 
metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S 
A. 2007; 104(18): 7432–7437, doi: 10.1073/pnas.0701600104, indexed 
in Pubmed: 17452648.
12. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor 
interaction and activation is determined by betaKlotho. J Cell Physiol. 
2008; 215(1): 1–7, doi: 10.1002/jcp.21357, indexed in Pubmed: 18064602.
13. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression 
analyses of mouse betaklotho, which encodes a novel Klotho family 
protein. Mech Dev. 2000; 98(1-2): 115–119, indexed in Pubmed: 
11044614.
14. Szymczyk A, Krzywański R, Forma E. Struktura i funkcje białka βKlotho. 
Folia Medica Lodziensia. 2013; 40: 99–132.
15. http://www.nextprot.org.
16. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes 
allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004; 
36(4): 417–422, doi: 10.1038/ng1330, indexed in Pubmed: 15034581.
17. Nojima M, Suzuki H, Toyota M, et al. Frequent epigenetic inactivation of 
SFRP genes and constitutive activation of Wnt signaling in gastric cancer. 
Oncogene. 2007; 26(32): 4699–4713, doi: 10.1038/sj.onc.1210259, 
indexed in Pubmed: 17297461.
18. Urakami S, Shiina H, Enokida H, et al. Combination analysis of 
hypermethylated Wnt-antagonist family genes as a novel epigenetic 
biomarker panel for bladder cancer detection. Clin Cancer Res. 2006; 
12(7 Pt 1): 2109–2211, doi: 10.1158/1078-0432.CCR-05-2468, indexed 
in Pubmed: 16609023.
19. Szymczyk A, Forma E, Krześlak A, et al. Genetic polymorphism of Klotho 
gene. Folia Medica Lodziensia. 2012; 39: 189–205.
20. Poh W, Wong W, Ong H, et al. Klotho-beta overexpression as a novel 
target for suppressing proliferation and fibroblast growth factor 
receptor-4 signaling in hepatocellular carcinoma. Mol Cancer. 2012; 23: 
11–14, doi: 10.1186/1476-4598-11-14, indexed in Pubmed: 22439738.
21. Ye X, Guo Yu, Zhang Qi, et al. βKlotho suppresses tumor growth in hepa-
tocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling path-
way. PLoS One. 2013; 8(1): e55615, doi: 10.1371/journal.pone.0055615, 
indexed in Pubmed: 23383245.
22. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets 
in cancer. Pharmacol Ther. 2010; 125(1): 105–117, doi: 10.1016/j.
pharmthera.2009.10.001, indexed in Pubmed: 19874848.
23. Liu Z, Qi S, Zhao X, et al. Metformin inhibits 17β-estradiol-induced 
epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 
signaling and AMPKα signaling in endometrial adenocarcinoma 
cells. Oncotarget. 2016; 7(16), doi: 10.18632/oncotarget.7040.
